Portal de Periódicos da CAPES

Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

2012; Lippincott Williams & Wilkins; Volume: 35; Issue: 8 Linguagem: Inglês

10.1097/cji.0b013e31826e8f5f

1537-4513

Shari Pilon‐Thomas, Lisa Kühn, Sabine Ellwanger, William E. Janssen, Erica Royster, Suroosh S. Marzban, Ragini R. Kudchadkar, Jonathan S. Zager, Geoffrey T. Gibney, Vernon K. Sondak, Jeffrey S. Weber, James J. Mulé, Amod A. Sarnaik,

Cancer Immunotherapy and Biomarkers

A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.